Postmenopausal hormone therapy, SERMs, and coronary heart disease in women

Journal of Endocrinological Investigation

Volumn 22, Issue 8, 1999, Pages 616-624

  Wenger, Nanette K ^a   Grady, D ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary hearth disease; Postmenopausal hormone therapy; SERM; Women

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; LIPOPROTEIN;

FEMALE; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; POSTMENOPAUSE; REVIEW;

EID: 0032848616     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343619     Document Type: Review

References (62)

1. Grady D., Rubin S.M., Petitti D.B., Fox C.S., Black D., Ettinger B., Ernster V.L., Cummings S.R. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 1992, 117: 1016-1037.
2. National Center for Health Statistics. Vital Statistics of the United States. US Department of Health and Human Services, Washington, DC, 1987, vol. 2, part A.
3. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995, 273: 199-208.
4. Barrett-Connor E., Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu. Rev. Pub. Health 1998, 19: 55-72.
5. Love R., Wiebe D., Feyzi J., Newcomb P., Chappell R. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 1994, 86: 1534-1539.
6. Walsh B., Kuller L., Wild R., Paul S., Farmer M., Lawrence J., Shah A., Anderson P. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998, 279: 1444-1451.
7. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev. Med. 1991, 20: 47-63.
8. Bush T.L., Barrett-Connor E., Cowan L.D., Criqui M.H., Wallace R.B., Suchindran C.M., Tyroler H.A., Rifkind B.M. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987, 75: 1102-1109.
9. Sullivan J.M., Vander Zwaag R., Hughes J.P., Maddock V., Kroetz F.W., Ramanathan K.B., Mirvis D.M. Estrogen replacement and coronary artery disease. Arch. Intern. Med. 1990, 150: 2557-2562.
10. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 1991, 151: 75-78.
11. O'Brien J.E., Peterson E.D., Keeler G.P., Berdan L.G., Ohman E.M., Faxon D.P., Jacobs A.K., Total E.J., Califf R.M. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J. Am. Coll. Cardiol. 1996, 28: 1111-1118.
12. Newton K.M., LaCroix A.Z., McKnight B., Knopp R.H., Siscovick D.S., Heckbert S.R., Weiss N.S. Estrogen replacement therapy and prognosis after first myocardial infarction. Am. J. Epidemiol. 1997, 145: 269-277.
13. Sullivan J.M., El-Zeky F., Vander Zwagg R., Ramanathan K.B. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am. J. Cardiol. 1997, 79: 847-850.
14. O'Keefe J.H., Kim S.C., Hall R.R., Cochran V.C., Lawhorn S.L., McCallister B.D. Estrogen replacement therapy after coronary angioplasty in women. J. Am. Coll. Cardiol. 1997, 29: 1-5.
15. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann. Intern. Med. 1991, 115: 455-456.
16. Matthews K.A., Kuller L.H., Wing R.R., Meilahn E.N., Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am. J. Epidemiol. 1996, 143: 971-978.
17. Berman R., Epstein R., Lydick E. Risk factors associated with women's compliance with estrogen replacement therapy. J. Women's Health 1997, 6: 219-226.
18. Brett K., Madans J. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am. J. Epidemiol. 1997, 145: 536-545.
19. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N. Engl. J. Med. 1980, 303: 1038-1041.
20. Fiebach N.H., Viscoli CM., Horwitz R.I. Differences between women and men in survival after myocardial infarction. JAMA 1990, 263: 1092-1096.
21. Gallagher E.J., Viscoli C.M., Horwitz R.I. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1993, 270: 742-744.
22. Espeland M., Marcovina S., Miller V., Wood P., Wasilauskas C., Sherwin R., Schrott H., Bush T. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation. 1998, 97: 979-986.
23. Mosca L., Jahnige K., Giacherio D., Christman G., Johnson T. Beneficial effect of hormone replacement therapy on lipoprotein(a) levels in postmenopausal women. Prev. Cardiol. 1999, 2: 51-58.
24. Guetta V., Cannon R.O. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996, 93: 1928-1937.
25. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoft V. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280: 605-613.
26. Nabulsi A., Folsom A., White A., Patsch W., Heiss G., Wu K., Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N. Engl. J. Med. 1993, 328: 1069-1075.
27. Ridker P. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease. Haemostasis 1997, 27 (Suppl 1): 2-11.
28. Paul S., Dean R., Tracy R., Cox D., Walsh B., Anderson P. Effects of raloxifene and hormone replacement therapy on homocysteine and C-reactive protein levels in postmenopausal women. Circulation 1998, 98(Suppl): 17-18 (abstract).
29. Karas R.H., Patterson B.L., Mendelsohn M.E. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994, 89: 1943-1950.
30. Chang W.C., Nakao J., Orimo H., Murota S.I. Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells. Biochim. Biophys. Acta. 1980, 620: 472-480.
31. Lieberman E.H., Gerhard M.D., Uehara A., Walsh B.W., Selwyn A.P., Ganz P., Yeung A.C., Creager M.A. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. 1994, 121: 936-941.
32. Rosano G.M.C., Sarrel P.M., Poole-Wilson P.A., Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet 1993, 342: 133-136.
33. Williams J. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990, 81: 1680-1687.
34. Reis S.E., Gloth ST., Blumenthal R.S., Resar J.R., Zacur H.A., Gerstenblith G., et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994, 89: 52-60.
35. Blumenthal R., Brinker J., Resar J., Gloth S., Zacur H., Coombs V., Gerstenblith G., Reis S. Long-term estrogen therapy abolishes acute estrogen-induced coronary flow augmentation in postmenopausal women. Am. Heart J. 1997, 733: 323-328.
36. Fischer-Dzoga K., Wissler R., Vesselinovitch D. The effect of estradiol on the proliferation of rabbit aortic medial tissue cells induced by hyperlipemic serum. Exp. Mol. Pathol. 1983, 39: 355-363.
37. Vargas R., Wroblewska B., Rego A., Hatch J., Ramwell P.W. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br. J. Pharmacol. 1993, 109: 612-617.
38. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S., Clarkson T.B. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Arteriosclerosis 1990, 70: 1051-1057.
39. CAST. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 1989, 321: 406-412.
40. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 1995, 85: 304-313.
41. Adams M.R., Register T.C., Golden D.L., Wagner J.D., Williams J.K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 1997, 17: 217-221.
42. Pirhonen J., Vuento M., Makinen J., Salmi T. Long-term effects of hormone replacement therapy on the uterus and on uterine circulation. Am. J. Obstet. Gynecol. 1993, 768: 620-630.
43. Sullivan J.M., Shala BA, Miller LA., Lerner J.L., McBrayer J.D. Progestin enhances vasoconstrictor responses in postmenopausal women receiving estrogen replacement therapy. Menopause 1995, 2: 193-199.
44. Sarrel P.M. How progestins compromise the cardioprotective effects of estrogens. Menopause 1995, 2: 187-190.
45. Coronary Drug Project Research Group. The Coronary Drug Project - initial findings leading to modifications of its research protocol. JAMA 1970, 274: 1303-1313.
46. Coronary Drug Project Research Group. The Coronary Drug Project - Findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA 1973, 226: 652-657.
47. Hemminki E., McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997, 315: 149-153.
48. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clin. Trials 1998, 19: 61-109.
49. Delmas P., Bjarnason N., Mitlak B., Ravoux A., Shah A., Huster W., Draper M., Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337: 1641-1647.
50. Fisher B., Costantino J., Wickerham D., Redmond C., Kavanah M., Cronin W., Vogel V., Robidoux A., Dimitrov N., Atkins J. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI 1998, 90: 1371-1388.
51. Cummings S., Eckert S., Kreuger K., Grady D., Norton L., Nickelsen T., Bjarnason N., Morrow M., Lippman M., Black D., Glusman J., Costa A., Jordan V. Raloxifene treatment is associated with reduced risk of breast cancer in postmenopausal women with osteoporosis. JAMA 1999, 281 (in press).
52. Cattaneo M., Baglietto L., Zighetti M., Bettega D., Robertson C., Costa A., Mannucci P., Decenzi A. Tamoxifen reduces plasma homocysteine levels in healthy women. Br. J. Cancer 1998, 77: 2264-2266.
53. Rahimian R., Laher I., Dube G., van Breemen C. Estrogen and selective estrogen receptor modulator LY117018 enhance release of nitric oxide in rat aorta. J. Pharmacol. Expr. Ther. 1997, 283: 116-122.
54. Loo S., Lesoon-Wood L., Cooney R. Effects of tamoxifen on nitric oxide synthesis and neoplastic transformation in C3H 10T1/2 fibroblasts. Cancer Lett. 1998, 122: 67-75.
55. Wiernicki T., Bean J., Dell C., Williams A., Wood D., Kauffman R., Singh J. Inhibition of vascular smooth muscle cell proliferation and arterial intimai thickening by a novel antiproliferative naphthopyran. J. Pharmacol. Expr. Ther. 1996, 278:1452-1459.
56. Clarkson T., Anthony M., Jerome C. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 1998, 83: 721-726.
57. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 339: 71-85.
58. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996, 275: 370-375.
59. Greendale G., Reboussin B., Hogan P., Barnabei V., Shumaker S., Johnson S., Barrett-Connor E. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet. Gynecol. 1998, 92: 982-988.
60. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350: 1047-1059.
61. Fisher B., Dignam J., Bryant J., DeCillis A., Wickerham D., Wolmark N., Costantino J., Redmond C., Fisher E., Bowman D. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 1996, 88: 1529-1542.
62. Fisher B., Costantino J., Redmond C., Fisher E., Wickerham D., Cronin W. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994, 86: 527-537.